Nonsteroidal anti-inflammatory drugs enhance glutathione S-transferase theta levels in rat colon

Biochimica et Biophysica Acta - General Subjects

Volumn 1381, Issue 3, 1998, Pages 305-311

  Van Lieshout, Esther M M ^a   Tiemessen, Dorien M ^a   Roelofs, Hennie M J ^a   Peters, Wilbert H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemoprevention; Colon cancer; Glutathione S transferase; GSTT1; Nonsteroidal anti inflammatory drug; Rat

Indexed keywords

ACETYLSALICYLIC ACID; GLUTATHIONE TRANSFERASE; IBUPROFEN; INDOMETACIN; MONOCLONAL ANTIBODY; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; POLYCLONAL ANTIBODY; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; COLON CANCER; CONTROLLED STUDY; DETOXIFICATION; DRUG EFFECT; ESOPHAGUS; GASTROINTESTINAL TRACT; INTESTINE EPITHELIUM; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STOMACH;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BUTANONES; COLON; COLONIC NEOPLASMS; DIET; GLUTATHIONE TRANSFERASE; IBUPROFEN; INDOMETHACIN; MALE; PIROXICAM; RATS; RATS, WISTAR; SULINDAC;

EID: 0031810856     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-4165(98)00042-7     Document Type: Article

References (55)

1. Brogden R.N., Heel R.C., Speight T.M., Avery G. Sulindac: a review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. Drugs. 16:1978;97-114.
2. Turner D., Berkel H.J. Nonsteroidal anti-inflammatory drugs for the prevention of colon cancer. Can. Med. Assoc. J. 149:1993;595-602.
3. Earnest D.L., Hixson L.J., Alberts D.S. Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention. J. Cell. Biochem. Suppl. 16I:1992;136-166.
4. Rosenberg L., Palmer J.R., Zauber A.G., Warshauer M.E., Stolley J.D., Shapiro S.A. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J. Natl. Cancer Inst. 83:1991;355-358.
5. Thun M.J., Namboodiri M.M., Heath C.W. Aspirin use and reduced risk of fatal colon cancer. New Engl. J. Med. 325:1991;1593-1596.
6. Thun J.M., Namboodiri M.M., Caller E.E., Flanders W.D., Heath C.W. Aspirin use and risk of fatal cancer. Cancer Lett. 53:1993;1322-1327.
7. Lancaster T., Silagy C. Aspirin and neoplasia of the digestive tract: is there a chemopreventive effect? Dig. Dis. 12:1994;170-176.
8. Luk G.D. Prevention of gastrointestinal cancer - the potential role of NSAIDs in colorectal cancer. Schweiz. Med. Wochenschr. 126:1996;801-812.
9. Reddy B.S., Rao C.V., Rivenson A., Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis. 14:1993;1493-1497.
10. Davis A.E., Patterson F. Aspirin reduces the incidence of colonic carcinoma in the dimethylhydrazine rat animal model. Aust. N.Z. J. Med. 24:1994;301-303.
11. Mereto E., Frencia L., Gjia M. Effect of aspirin on incidence and growth of aberrant crypt foci induced in rat colon by 1,2-dimethylhydrazine. Cancer Lett. 76:1994;5-9.
12. Reddy B.S., Tokuno K., Kulkarni N., Aligia C., Kelloff G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis. 13:1993;1019-1023.
13. Jalbert G., Castonguay A. Effects of NSAID's on NNK-induced pulmonary and gastric tumorigenesis in A/J mice. Cancer Lett. 66:1992;21-28.
14. Narisawa T., Sato M., Tani M., Kudo T., Guo A. Inhibition of development of methylnitrosurea-induced rat colon tumours by indomethacin treatment. Cancer Res. 41:1981;1954-1957.
15. Tanaka T., Kojima T., Yoshimi N., Sugie S., Mori H. Inhibitory effect of the non-steroidal anti-inflammatory drug indomethacin on the naturally occurring carcinogen, 1-hydroxyanthraquinone in male ACI/N rats. Carcinogenesis. 12:1991;1949-1952.
16. Taton G., Servais P., Galand P. Modulation by indomethacin or prostaglandin E2 of the incidence of diethylnitrosamine-induced glutamyltranspeptidase positive foci in rat liver. Jpn. J. Cancer Res. 81:1990;747-753.
17. Tanaka T., Kojima T., Okomura A., Sugie S., Mori H. Inhibitory effect of the non-steroidal anti-inflammatory drugs indomethacin and piroxicam on 2-acetaminofluorene-induced hepatocarcinogenesis in male ACI/N rats. Cancer Lett. 68:1993;111-118.
18. Pollard M., Luckert P.H. Prolonged antitumor effect of indomethacin on autochthonous intestinal tumours in rats. J. Natl. Cancer Inst. 70:1983;1103-1105.
19. Kudo T., Narisawa T., Abo S. Antitumour activity of indomethacin on methylazoxymethanol-induced large bowel tumours in rats. Jpn. J. Cancer Res. 71:1980;260-264.
20. Rubio C.A. Antitumoral activity of indomethacin on experimental oesophageal tumours. J. Natl. Cancer Inst. 72:1984;705-707.
21. Rubio C.A. Further studies on the therapeutic effect of indomethacin on oesophageal tumours. Cancer. 58:1986;1029-1031.
22. Pollard M., Luckert P.H. Effect of piroxicam on primary intestinal tumours induced in rats by N-methylnitrosurea. Cancer Lett. 25:1984;117-121.
23. Rao C.V., Tokuno K., Rigotti J., Zang E., Kelloff G., Reddy B.S. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, α-difluoromethylornithine, 16α-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res. 51:1991;4528-4534.
24. Reddy B.S., Nayini J., Tokuno K., Rigotti J., Zang E., Kelloff G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res. 50:1990;2562-2568.
25. Reddy B.S., Maruyama H., Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumour development. Cancer Res. 47:1987;5340-5346.
26. Pollard M., Luckert P.H., Schmidt M.A. The suppressive effect of piroxicam in autochthonous intestinal tumours in the rat. Cancer Lett. 21:1983;57-61.
27. Rao C.V., Rivenson A., Simi B., Zang E., Kelloff G., Steele V., Reddy B.S. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 55:1995;1464-1472.
28. van Lieshout E.M.M., Tiemessen T.M., Peters W.H.M., Jansen J.B.M.J. Effects of nonsteroidal anti-inflammatory drugs on glutathione S-transferases of the rat digestive tract. Carcinogenesis. 18:1997;485-490.
29. Smith W.L., Marnett L.J. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim. Biophys. Acta. 1083:1991;1-17.
30. Webb D.R., Osheroff P.L. Antigen stimulation of prostaglandin synthesis and control of immune response. Proc. Natl. Acad. Sci. USA. 73:1976;1300-1304.
31. Craven P.A., Saito R., DeRubertis F.R. Role of local prostaglandin synthesis in the modulation of proliferative activity of rat colonic epithelium. J. Clin. Invest. 72:1983;1365-1375.
32. Lupescu A. Enhancement of carcinogenesis by prostaglandins. Nature. 272:1978;634-636.
33. Lynch N.R., Castes M., Astoin M., Salomon J.C. Mechanisms of inhibition of tumour growth by aspirin and indomethacin. Br. J. Cancer. 38:1978;503-512.
34. Brooks P.M., Wood J.J. Nonsteroidal antiinflammatory drugs - differences and similarities. New Engl. J. Med. 324:1991;716.
35. Beckett G.J., Hayes J.D. Glutathione S-transferases: biomedical applications. Adv. Clin. Chem. 30:1993;281-380.
36. Hayes J.D., Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and contribution of the isoenzymes to cancer chemoprevention and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30:1995;445-600.
37. Pemble S., Schroeder K.R., Spencer S.R., Meyer D.J., Hallier E., Bolt H.M., Ketterer B., Taylor J.B. Human glutathione S-transferase theta (GSTT1-1): cDNA cloning and the characterization of a genetic polymorphism. Biochem. J. 300:1994;271-276.
38. Tan K.L., Webb G.C., Baker R.T., Board P.G. Molecular cloning of a cDNA and chromosomal localization of a human theta class glutathione S-transferase gene (GSTT2) to chromosome 22. Genomics. 25:1995;381-387.
39. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
40. Juronen E., Tasa G., Uusküla M., Pooga M., Mikelsaar A.-V. Production and characterization of monoclonal antibodies against class theta glutathione S-transferase T1-1. Hybridoma. 15:1996;77-82.
41. Nijhoff W.A., Groen G.M., Peters W.H.M. Induction of rat hepatic and intestinal glutathione S-transferases and glutathione by dietary naturally occurring anticarcinogens. Int. J. Oncol. 3:1993;1131-1139.
42. van Lieshout E.M.M., Peters W.H.M., Jansen J.B.M.J. Effect of oltipraz, α-tocopherol, β-carotene, and phenethylisothiocyanate on rat oesophageal, gastric, colonic and hepatic glutathione, glutathione S-transferases and peroxidases. Carcinogenesis. 17:1996;1439-1445.
43. Narisawa T., Satoh M., Sano M., Takahashi T. Inhibition of initiation and promotion by N-methylnitrosurea-induced colon carcinogenesis in rats by non-steroidal anti-inflammatory agent indomethacin. Carcinogenesis. 4:1983;1225-1227.
44. Pollard M., Luckert P.H. Prevention and treatment of primary intestinal tumours in rats by piroxicam. Cancer Res. 49:1989;6471-6473.
45. Craven P.A., DeRubertis F.R. Effects of aspirin on 1-dimethylhydrazine-induced colonic carcinogenesis. Carcinogenesis. 13:1992;541-546.
46. Giardiello F.M. Sulindac and polyp regression. Cancer Metastasis Rev. 13:1994;279-283.
47. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P., Booker S.V., Robinson C.R., Offerhaus G.J.A. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. New Engl. J. Med. 328:1993;313-1316.
48. Labayle D., Fischer D., Vielh P., Drouhin F., Pariente A., Bories C., Duhamel O., Trousset M., Attali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 101:1991;635-639.
49. Ploemen J.H., Wormhoudt L.W., van Ommen B., Commandeur J.N., Vermeulen N.P., van Bladeren P.J. Polymorphism in the glutathione conjugation activity of human erythrocytes towards ethylene dibromide and 1,2-epoxy-3-(p-nitrophenoxy)propane. Biochim. Biophys. Acta. 1243:1995;469-476.
50. Peters W.H.M., Nagengast F.M., van Tongeren J.H.M. Glutathione S-transferase, cytochrome P450, and uridine 5′-diphosphate-glucuronosyltransferase in human small intestine and liver. Gastroenterology. 96:1989;783-789.
51. Peters W.H.M., Kock L., Nagengast F.M., Kremers P.G. Biotransformation enzymes in human intestine: critical low levels in the colon? Gut. 32:1991;408-412.
52. Deakin M., Elder J., Hendrickse C., Peckham D., Baldwin D., Pantin C., Wild N., Leopard P., Bell D.A., Jones P., Duncan H., Brannigan K., Alldersea J., Fryer A.A., Strange R.C. Glutathione S-transferase GSTT1 genotype and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis. 17:1996;881-884.
53. Chevenix-Trench G., Young J., Coggan M., Board P. Glutathione S-transferase M1 and T1 polymorphisms: susceptibility to colon cancer and age of onset. Carcinogenesis. 16:1995;1655-1657.
54. Katoh T., Nagata N., Kuroda Y., Itoh H., Kawahara A., Kuroki N., Ookuma R., Bell D.A. Glutathione S transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. Carcinogenesis. 17:1996;1855-1859.
55. Nelson H.H., Wiencke J.K., Chrisiani D.C., Cheng T.J., Zuo Z.F., Schwartz B.W., Lee B.K., Spitz M.R., Wang M., Xu X., Kelsey K.T. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis. 16:1995;1243-1245.